The local tumor microbiome is associated with survival in late-stage colorectal cancer patients

Justine W. Debelius^{1,2},* Lars Engstrand¹, Andreas Matussek^{3, 4, 5}, Nele Brusselaers^{1,6,7}, James T. Morton⁸, Margaretha Stenmarker^{9,10}, Renate S. Olsen^{1,9,11}*

¹Centre for Translational Microbiome Research, Department of Microbiology, Tumor, and Cell biology. Karolinska Institutet, Solna, Sweden

²Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health. Baltimore,

MD, USA

³Laboratory Medicine, Jönköping Region County, Department of Clinical and Experimental Medicine, Linköping University, Jönköping, Sweden

⁴Division of Laboratory Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway

⁵Department of Microbiology, Division of Laboratory Medicine, Oslo University Hospital, Oslo, Norway

⁶Global Health Institute, Antwerp University, Antwerp, Belgium

⁷Department of Head and Skin, Ghent University, Ghent, Belgium

⁸ Biostatistics & Bioinformatics Branch, Eunice Kennedy Shriver National Institute of Child

Health and Human Development, National Institutes of Health, Bethesda, MD, USA

⁹Futurum/Department of Pediatrics, Region Jönköping County, and Department of Clinical and

Experimental Medicine, Linköping University, Linköping, Sweden

¹⁰The Institute of Clinical Sciences, Department of Paediatrics, the Sahlgrenska Academy at the University of Gothenburg, Sweden

¹¹Department of Pathology, Division of Laboratory Medicine, Oslo University Hospital,

Norwegian Radium Hospital, Oslo, Norway.

*Corresponding Authors: Renate Slind Olsen, e-mail:resols@ous-hf.no; Justine Debelius email:

justine.debelius@jhu.edu

Word Count: 3795

ABSTRACT

<u>Objective</u> Colorectal cancer survival has been linked to the microbiome. Single organism analyses suggest *Fusobacterium nucleatum* as a marker of poor prognosis. However, *in situ* imaging of tumors demonstrate a polymicrobial tumor-associated community. To understand the role of these polymicrobial communities in survival, we performed an untargeted study of the microbiome in late-stage colorectal cancer patients.

<u>Design</u> We conducted a nested case-control study in late-stage cancer patients undergoing resection for primary adenocarcinoma. The microbiome of paired colorectal tumor and adjacent tissue samples was profiled using 16S rRNA sequencing; we used compositionally aware ordination and differential ranking to profile the microbial community.

<u>Results</u>. We found a consistent difference in the microbiome between paired tumor and adjacent tissue, despite strong individual microbial identities. Tumors had higher relative abundance of genus *Fusobacteria* and *Campylobacter* at the expense of members of families Lachnospriaceae and Rumminococeae. Furthermore, a larger difference between normal and tumor tissue was associated with prognosis: patients with shorter survival had a larger difference between normal and tumor tissue. We found the difference was specifically related to taxa previously associated with cancer. Within the tumor tissue, we identified a 39 member community statistic associated with survival; for every log2 fold increase in this value, an individual's odds of survival increased by 20% (OR survival 1.20; 95% CI 1.04, 1.33).

Conclusion Our results suggest that a polymicrobial tumor-specific microbiome is associated

with survival in late-stage colorectal cancer patients.

1 INTRODUCTION

3	Globally, colorectal cancer (CRC) is the second most common cause of cancer-related death and
4	CRC-related mortality has been increasing since 2000 (1,2). One potentially modifiable area of
5	interest in CRC survival is the gut microbiome. In a healthy gut, the intestinal microbiome
6	contributes to homeostasis through epithelial cell renewal, maintaining gut barrier integrity, and
7	immune modulation (3,4). However, CRC patients have demonstrated a consistently altered gut
8	microbiome compared to healthy controls, including a higher relative abundance of organisms
9	more commonly found in the oral cavity (5,6). Meta-analyses using targeted analyses show high
10	levels of Fusobacterium nucleatum (F. nucleatum) in tumor tissue are detrimental to survival
11	(7,8).
12	
13	Fewer studies have explored the relationship between the gut microbiome and CRC prognosis
14	using untargeted sequencing. Untargeted techniques can better characterize the bacterial
15	community, and the ways in which potentially pathogenic organisms might interact with a host's
16	unique, stable, microbiome (9–11). In situ microscopy shows that tumor tissue is colonized by a
17	polymicrobial biofilm including Fusobacteria, Proteobacteria, Bacteroidetes, and
18	Lachnospriaceae; monoculture biofilms have not been observed (12). Biofilms are also
19	frequently localized to tumors, and paired normal tissue samples are rarely colonized, suggesting
20	a localized effect and potential difference between tumor and adjacent tissue (12).
21	
22	Previous untargeted studies of the gut microbiome and colorectal cancer survival have either
23	focused exclusively on the tumor tissue (13) or have treated the tumor and adjacent tissue as

24	identical (14). Paired biopsy studies provide clues about whether local and global regulation of
25	the microbiome drives tumorigenesis, although many paired studies have failed to account for
26	survival (12,15–19), and in some cases, struggled to characterize the microbiome due to
27	technical (19) or analytical (13-17) issues.
28	
29	To address the gaps in knowledge, we followed 101 late-stage CRC patients recruited from a
30	hospital in southern Sweden who underwent surgical resections of primary adenocarcinoma
31	between 1997-2017. Patients were categorized into short- or long-term survivors based on their
32	relapse free survival (less than two years or five or more years, respectively). We examined the
33	relationship between the microbiome of colorectal tumors and adjacent normal tissue and
34	survival, accounting for clinical covariates.
35	
36	METHODS
37	
38	Study Population
39	Patients were recruited from all consecutive CRC patients (n=540) who underwent surgical
40	resection for primary colorectal adenocarcinoma at the Department of Surgery, Ryhov County
41	Hospital, Region of Jönköping County, Jönköping, Sweden between 1997 and 2017. Patients
42	with tumor-node-metastasis (TNM) stage III and IV cancer who had matched biopsies from
43	normal and tumor tissue (n=116) were selected. Patient characteristics, including demographic,
44	surgical, pathological information, and outcome were determined from a review of medical
45	records.
46	

47	The final study cohort included patients with paired high quality microbiome samples (n=101).
48	Fifteen individuals were excluded due to insufficient sequencing depth in the tumor (n=8) or
49	normal (n=7) tissue sample. There was no difference in the survival status in the samples with
50	insufficient sequencing depth. Our final cohort included matched tumor- and normal tissue
51	samples (≥ 10 cm apart from tumor tissue) from 51 long- (≥ 5 year survival) and 50 short-term (≤ 2
52	year survival) survivors.
53	
54	The study was approved by the Regional Ethical Review Board in Linköping, Linköping,
55	Sweden (98113, 2013/271-31); a written informed consent was obtained from each patient.
56	
57	There was no patient or public involvement in this retrospective study.
58	
59	Statistical Analysis of patient characteristics
60	A multivariable logistic regression was used to assess the predictive impact of the following
61	patient, cancer and treatment related characteristics: age (categorized as <60, 60-69, 70-74, ≥75
62	years), sex (female or male), American Society of Anesthesiologists physical status (ASA) score
63	(I-healthy, II-mild, III-IV-severe; patients with V-VI were not eligible for surgery); localization
64	of tumor (colon right, colon left, rectum), TNM stage (III or IV), grade of differentiation (from
65	low differentiation to high differentiation, with the latter more closely resembling non-cancer
66	histology); radical surgery (yes or no); period of surgery (1997-2005; 2006-2010; 2011-2017).
67	All results are expressed as Odds Ratios (ORs) and 95% Confidence Intervals (CIs) and the
68	calculations were conducted with Stata MP14 (Stata Corp, Texas).

70 Microbiome Sequencing

71	Paired tumor and normal tissue samples were collected during surgery. Tissue samples were
72	frozen directly and stored at -80°C until use. Samples were processed as previously described
73	(20). Briefly, DNA was extracted from tissue samples using physical and chemical lysis for
74	extraction. The 16S rRNA amplicon library was amplified with 341F/805R primers
75	(CCTACGGGNGGCWGCAG, GGACTACHVGGGTATCTAAT) using a program with 20
76	cycles (21). The samples were sequenced with a 2x300 approach using an Illumina MiSeq (San
77	Diego, CA, USA).
78	
79	The demultiplexed reads were denoised using the DADA2 algorithm (v1.13.1) in R (22). After
80	reads were demultiplexed and primers were trimmed, forward reads were trimmed to 265
81	nucleotides (nt) and reverse reads were trimmed to 225nt; the error rate model was trained on
82	15% of the reads. Reads were joined with at least 30nt overlap, and anything shorter than 380nt
83	after joining was discarded. Taxonomic assignment was performed using the naïve Bayesian
84	classifier implemented in DADA2 against the Silva 128 database (23,24). The amplicon
85	sequence variant (ASV) table from DADA2, taxonomy, and representative sequences were
86	imported into QIIME 2 (v. 2020.11) for further processing (25). A phylogenetic tree was built
87	using fragment insertion using the SEPP algorithm into the Silva 128 backbone with q2-
88	fragment-insertion (24-26). The table and sequences were filtered to exclude any ASV without
89	phylum level annotation or which could not be inserted into the phylogenetic tree.
90	
~ .	

91 Microbiome Community Characterization

92 Between sample (beta) diversity

For paired sample analysis, we calculated unweighted UniFrac (27), weighted UniFrac (28), and
binary Jaccard (29) distances and Bray-Curtis dissimilarity (30) on a feature table rarified to
2500 sequences/sample (31). Aitchison distance was calculated on unrarefied data with a
pseudo-count of 1 (32,33). Beta diversity metrics were calculated using the q2-diversity plugin in
OIIME 2 (25).

98

99 Compositional Tensor Factorization ordination

100 To account for subject-specific effects on ordinations, we used compositional tensor fraction

101 (CTF) for paired samples using the Gemelli qiime2 plugin (0.7.0) (34). Features were filtered to

102 exclude those present in fewer than 20 samples or less than 100 total counts. The distance in CTF

103 subject space was calculated as the Euclidean distance between subject coordinates. The

104 difference in intra-individual CTF space between normal and tumor tissue (ΔPC) were compared

105 using the subject-state coordinates and feature-state coordinates, respectively.

106

107 Robust Principal Components Analysis

108 For each tissue type, we examined beta diversity using a Robust Principal Components Analysis

109 (rPCA) using the DEICODE algorithm (v. 0.2.4) (35). For a given sample set, we filtered

110 filtering features present in less than 10% of samples (n=10) or with fewer than 10 total counts.

111 The auto-rPCA function was used to select the appropriate number of principle components

112 (PCs) for the data. The PCs were divided into quartiles and dichotomized along the median

113 value.

115	For tissue types where there was a significant association between a component and survival, we
116	selected features which might be associated with outcome. Communality was calculated as the
117	square root of the sum of squares across all PC. Features with a communality value of at least
118	0.01 were selected as candidates for the additive log ratio (ALR) calculation (n=130). A
119	pseudocount of 1 was added before the ALR calculation. The ALR was calculated as the log2
120	ratio of features more extreme that the fourth quartile of samples over feature more extreme than
121	the first quartile. Continuous ALR values or ALR divided into tertials were used for regression.
122	
123	Differential Ranking
124	We performed hypothesis generating differential abundance testing between tumor and normal
125	tissue using a modified differential ranking (DR) technique (36,37). We first filtered the table to
126	remove any feature with a relative abundance of less than 1/1000 in fewer than 10% of samples,
127	leaving 243 features for testing. We then used a modified Bayesian method for DR testing. ASV
128	counts were modeled through a negative binomial process. We started with naive priors of a
129	between 0-and 5-fold change in a ASV and fit the model using 4000 iterations. The data was fit
130	to a linear mixed effects model using subject as a random intercept, modeling either for tissue or
131	for the intersection between tissue and survival. Modeling was done with pystan (v 3.4.0) within
132	the QIIME 2 2021.11 conda environment (38,39).
133	
134	We used the ranks to identify "extreme" features. Starting from the feature with the strongest

we used the ranks to identify extreme features. Starting from the feature with the strongest
signal associated with each possible value for a variable (e.g. normal vs tumor, short vs long
survival), we added features until every sample contained at least one of the extreme features. A

pooled ALR was calculated as the sum of all normal-tissue associated features over the tumor-associated features.

139

140 Statistical Analysis

- 141 Paired distances were extracted as the distance between an individual's tumor and adjacent
- 142 normal tissue. Interindividual distance was compared to the interindividual distance to samples
- 143 of the same tissue type, anatomical location, and survival group with a permutative two sample t-
- 144 test with 999 permutations.

145

146 Associations with per-subject CTF coordinates were checked by calculating the Euclidean

147 distance between samples and applying a permanova test with 999 permutations in scikit-bio (v.

148 0.5.6) (40). The change between tissue types in CTF coordinate space were modeled with a

149 paired sample t-test was used to determine if there was a global difference between tumor and

150 normal tissue along either PC; the effect of change on survival was compared using a

151 permutative Welch's t-test looking at the difference between groups with 999 permutations. ALR

152 interactions were evaluated using a linear mixed effects model with individual as the grouping

153 factor.

154

155 Survival was modeled using logistic regression. Models were fit using a crude (unadjusted)

156 model and a model adjusted for age, sex, ASA score, tumor location, surgery period, TNM stage,

157 radical surgery, and differentiation grade.

158

159 For all analyses, a p-value of 0.05 was considered significant.

160

- 161 Modeling was performed using statsmodels (v 0.11.1), scipy (v 1.4.1), and numpy (v 1.18.5) in
- 162 python (v. 3.6) (41–43). Figures were plotted using with matplotlib (3.2.2) and seaborn (0.10.1)
- 163 The dendrogram was plotted using Empress (q2-empress v.0.0.1-dev, commit b705358) (44);
- 164 three dimensional ordinations were rendered using Emperor (v. 1.0.3) (45). Taxonomic colors
- 165 come from the microshades colorblind friendly palette (46). Figures were assembled in Adobe
- 166 Illustrator 2021 (Adobe Inc, San Jose, CA, USA).

168 **RESULTS**

169

170	In our nested case-control study of late-stage colorectal cancer patients, the 51 long-term
171	survivors were more likely to be younger, male, and healthier compared to the 50 short-term
172	survivors (Table S1). The short-term survivors presented with metastatic tumors and lower
173	differentiation than long-term survivors, and fewer received radical surgery. We found that age,
174	TNM stage and tumor differentiation were strong predictors of long-term survival (Table 1).
175	Individuals aged between 70-74 years were 14 times more likely to be short-term survivors (OR
176	14.24; 95% CI 1.21, 167.40) than those younger than 60. TNM-stage IV was associated with an
177	almost 50 times higher risk of being a short-term survivor (OR 49.32; 95% CI 5.86, 415.12)
178	compared to TNM stage III (Table 1).
179	
180	Following sequencing, quality filtering, and denoising to ASVs, we retained 202 paired tumor
181	and adjacent normal tissue samples. The broad pattern in the overserved microbiome reflect
182	those seen in previous studies of Swedish adults (Figure S1) (47). We found the patient was the
183	strongest predictor of microbiome composition, and that an individual's paired samples were

184 more similar to each other than tissue samples from patients with similar characteristics (Figure

185 S2), reflecting what appears to be a common pattern in CRC patients and beyond (10,18,48).

	Crude risk		ted risk
		Model 1 ¹	Model 2^2
	OR (95% CI)	OR (95% CI)	OR (95% CI)
Patient characteristics at time of surg	ery		
Age, years			
<60	1.00 (ref)	1.00 (ref)	1.00 (ref)
60-69	0.87 (0.24-3.09)	2.45 (0.26-22.72)	2.59 (0.28-24.38)
70-74	2.40 (0.65-8.81)	12.55 (1.06-149.26)	14.24 (1.21-167.40
≥75	1.96 (0.56-6.91)	8.68 (0.79-95.19)	10.55 (0.99-112.75
Sex			
Female	1.00 (ref)	1.00 (ref)	1.00 (ref)
Male	0.76 (0.35-1.67)	0.47 (0.14-1.56)	0.44 (0.13-1.41)
ASA score			
I (healthy)	1.00 (ref)	1.00 (ref)	1.00 (ref)
II (mild)	0.80 (0.32-2.02)	2.29 (0.45-11.78)	2.69 (0.56-12.96)
III-IV (severe or worse)	2.01 (0.65-6.19)	4.10 (0.60-27.92)	4.99 (0.79-31.45)
Pre-operative treatment			
None	1.00 (ref)	1.00 (ref)	-
Radiotherapy	1.17 (0.74-1.84)	0.71 (0.12-4.15)	-
Tumor characteristics			
Localization			
Colon right	1.00 (ref)	1.00 (ref)	1.00 (ref)
Colon left	0.47 (0.16-1.32)	0.78 (0.16-3.82)	0.76 (0.16-3.63)
Rectum	0.72 (0.28-1.84)	2.03 (0.33-12.63)	1.61 (0.36-7.21)
Mucinous cancer			
no	1.00 (ref)	1.00 (ref)	-
yes	0.83 (0.24-2.93)	0.50 (0.05-5.39)	-
TNM stage			
III	1.00 (ref)	1.00 (ref)	1.00 (ref)
IV	10.8 (3.68-31.72)	44.67 (5.53-360.63)	49.32 (5.86-415.12
Grade of differentiation			
Low	1.00 (ref)	1.00 (ref)	1.00 (ref)
Medium	0.20 (0.07-0.54)	0.23 (0.05-0.98)	0.24 (0.06-1.00)
High	0.21 (0.05-0.97)	0.09 (0.01-1.24)	0.10 (0.01-1.27)
Surgical characteristics			
Period of surgery			
1997-2005	1.00 (ref)	1.00 (ref)	1.00 (ref)
2006-2010	0.54 (0.21-1.37)	0.44 (0.10-1.92)	0.44 (0.10-1.89)
2011-2017	0.59 (0.21-1.65)	1.19 (0.22-6.47)	1.08 (0.22-5.36)
Radical operation			
no	1.00 (ref)	1.00 (ref)	1.00 (ref)
yes	0.05 (0.01-0.41)	0.13 (0.01-1.51)	0.12 (0.01-1.34)

Table 1. Risk factors for short-term survival

¹ Adjusted for all variables
 ² Adjusted for all other variables except for preoperative treatment and mucinous cancer

187 The microbiome of tumor and normal tissue differ

188 To address individual microbial identities, we applied a subject-aware compositional tensor 189 factorization (CTF) technique (34). The approach integrates feature-based information from each 190 sample to build both a subject-specific profile, and to describe changes within subjects and 191 features across a gradient. We did not find a statistically significant association between a sample's position in CTF space and survival (unadjusted permanova $R^2=0.012$; p=0.296, 999 192 193 permutation, Figure S3, Table S2). However, we found differences between normal and tumor 194 tissue, with a consistent shift between paired samples in CTF space, primarily along principal 195 component (PC) 2 and PC 3 (Figure 1A-D). 196 197 Given evidence of consistent, community-level changes in the microbiome between the tissue 198 types, we looked for features, which might be driving these differences. We used an individual-199 aware differential ranking technique, which first ranked the features with the greatest differences 200 associated with tissue type, and then we selected a subset of these features to build an additive 201 log ratio (ALR), a summary of taxa which likely describe the difference (Figure 1E, Table S3, 202 Files S1). We found tumor tissue was associated with a higher relative abundance of 203 Fusobacteria, Porphyromonas, Granulicatella, and Campylobacter at the expense of members 204 of genus *Blautia*, and *Ruminococcus*. Tumor tissue had a 1.78 (95% CI 1.50, 2.18, $p < 1x10^{-12}$) 205 log2-fold increase in the features selected by DR compared to normal tissue, suggesting a tissue-206 specific signature (Figure 1F). 207



Figure 1. There is a difference in the microbiome between tumor and normal tissues

We found a global pattern separating tumor and normal tissue can be seen in CTF ordination space. (A) Plotting the change between normal tissue and tumor tissue in PC 2 and PC 3 as a vector with normal tissue as the center demonstrates a clear directional pattern. The difference between normal and tumor tissue can also be seen along individual components: (B) PC 1, (C) PC 2, and (D) PC 3. Ticks and dashed zero-lines along PC 2 (B) and PC 3 (D) match the two-dimensional axes in (A). All boxplots are shown with a Cohen's d effect size statistic for a one-sided t-test and p-values from a permutative one sample t-test, 999 permutations. (E) Differential ranking of 300 abundant features identified normal tissue-associated features (light pink) and tumor-tissue associated features (dark pink). The inset shows selected features in each group, colored by family, colors are defined in the legend. (F) The change in the ALR between normal and tumor tissue. Coefficient from linear mixed effect model comparing the change based on tissue type; $p < 1x10^{-12}$.

Differences between normal- and tumor-associated microbiome are associated with survival

209	Since we saw consistent differences between tumor and normal tissue, we wondered if there
210	might be a relationship between the magnitude of the difference and survival. We found that
211	tumor and normal tissue were more similar in long-term survivors than short-term, a difference
212	primarily driven by changes in abundance (Table S4). Additionally, long-term survivors showed
213	a larger change along PC 2 compared to short-term survivors (Cohen's d 0.40, p=0.016, 999
214	permutations; Figure 2). This suggested enough of a community-level change in the microbiome
215	to motivate looking for features which might explain the differences.
216	
217	Therefore, we applied a subject-aware differential ranking technique looking at the interaction
218	between tissue type and survival to further refine the features (Figure 2E-G). We used an
219	interaction model to identify features that changed in tumor tissue based on survival group.
220	Based on the tissue associated taxa associated with long-term survival, we defined an ALR
221	where tumor tissue was associated with ASVs from genus Fusobacterium, Campylobacter, and
222	Escherichia/Shigella. We found members of genus Butyricicoccus, Roseburia, and Streptococcus
223	associated with both normal and tumor tissue (Table S5, File S2). There was a higher relative
224	abundance of the tumor-associated organisms in both survival groups, and the overall relative
225	abundance was higher in short-term survivors (Figure 2F). However, the magnitude of the
226	change did not differ between the two groups.
227	



Figure 2. The magnitude of the difference between tumor and normal tissue is associated with survival

There is a difference in the magnitude of change between long-term and short-term survivors. (A) In two dimensions, the change along PC2 and PC3 is visualized as a vector from normal tissue to tumor issue. Short-term survivors (<2 year) are shown in light blue. Long term survivors (\geq 5 years) are shown in dark blue. The corresponding relationships can be visualized along the individual components: (B) PC 1, (C) PC 2, and (D) PC 3. Ticks along PC 2 (C) and PC 3 (D) match the two-dimensional axes in (A). All boxplots are shown with a Cohen's d effect size, and p-value from a permutative Welch's t-test with 999 permutations, comparing the two survival groups. (E-H) A differential ranking model was fit to consider

the interaction between survival and tissue. The ranks associated with (E,F) tumor tissue in long-term survivors and (G,H) tumor tissue in short survivors (interaction) are show. (E,F) The relative associated with the model, insets highlight ASVs associated with the extremes of each group. Taxonomic assignments are provided in the legend. (F,H) The additive long ratio associated with the ranks. Paired differences are connected by a line between normal (N) and tumor (T) tissue. The effect was modeled using a linear mixed effects model, treating the individual as random. *p < 0.05, **p \leq 0.01, ***p \leq 0.001.

228	In contrast, the interaction term identified a set of taxa, which were significantly different
229	between the tissue types in short-term survivors but not among long-term survivors (Figure 2G,
230	Table S6, File S2). Once again, we found tumor tissue in short-term survivors to be strongly
231	associated with an ASV from Fusobacteria and as well as a few members of family
232	Veillonellaceae, although again, there were not clear taxonomic patterns in other families, such
233	as family Lachnospiraceae or Rumminococeae. These results indicate the survival-associated
234	changes in the microbiome may be largest in tumor tissue and help to identify specific set of
235	organisms responsible for these changes.
236	
237	The tumor microbiome is associated with survival
238	Based on our observation that differences in tissue types were more pronounced in short-term
239	survivors, and since past work focused on tumor tissues, we also chose to further interrogate the
239 240	survivors, and since past work focused on tumor tissues, we also chose to further interrogate the tumor-specific microbiome. A rPCA approach showed separation in the microbiomes between
240	tumor-specific microbiome. A rPCA approach showed separation in the microbiomes between
240 241	tumor-specific microbiome. A rPCA approach showed separation in the microbiomes between short- and long-term survivors (Figure 3A, D) (34). After adjustment for confounders and both
240 241 242	tumor-specific microbiome. A rPCA approach showed separation in the microbiomes between short- and long-term survivors (Figure 3A, D) (34). After adjustment for confounders and both PCs, patients with larger values for PC 1 had 3.5 lower (OR 0.29; 95% CI 0.08, 0.97) odds of
240241242243	tumor-specific microbiome. A rPCA approach showed separation in the microbiomes between short- and long-term survivors (Figure 3A, D) (34). After adjustment for confounders and both PCs, patients with larger values for PC 1 had 3.5 lower (OR 0.29; 95% CI 0.08, 0.97) odds of short-term survival, while those with higher values for PC 2 were five times less likely to be
 240 241 242 243 244 	tumor-specific microbiome. A rPCA approach showed separation in the microbiomes between short- and long-term survivors (Figure 3A, D) (34). After adjustment for confounders and both PCs, patients with larger values for PC 1 had 3.5 lower (OR 0.29; 95% CI 0.08, 0.97) odds of short-term survival, while those with higher values for PC 2 were five times less likely to be short-term survivors (OR 0.19; 95% CI 0.05, 0.80). Individuals in the quadrant defined by these



Figure 3. The tumor-associated microbiome is associated with survival

(A) Robust Principal Components Analysis (rPCA) ordination colored by short- (light) or long-(dark) term survival. Marginal axes show the distribution of points along each PC. The ordination is centered at the median distribution of points in each axis. (B) Phylogenetic tree showing the ASVs with PC 1. The tips and first heatmap are colored with taxonomic information. Heatmaps from left to right show the taxonomic assignment, mean central log ratio (CLR) relative abundance (viridis), the mean difference in CLR between long- and short-term survivors; whether the feature was used in the additive log ratio (ALR) calculation for PC 1 (teal - left; brown - right); the feature loading along PC 1; whether the feature was used in the PC 2 ALR calculation (green - bottom, purple top); the feature loadings along PC 2, coordinates to the top on the left; and whether the feature was included in the tumor survival index (light pink - lower value, dark pink - higher value). (C,D) Boxplot of the ALR of most extreme ranked taxa along selected based on (C) PC 1 and (D) PC 2. Axes are labeled to indicate the directionality of the log ratio calculation, label colors match panel (B). (E) Log odds of survival based on separation along the median of the PCs or grouping in the ALR shown in Light gray values are crude, dark gray are adjusted for age, sex, surgery year, tumor location, ASA score, differentiation grade, TNM stage. PC weights are adjusted for the position along the other PC; ALRs are not co-adjusted.

248	We found 37 features associated with separation along PC 1. To the left of PC 1, we found
249	members of genus Fusobacterium, Parvimonas and Porphyromonas, and other common oral
250	genera like Gemella and Dialster (Figure 3B). In contrast, higher values along PC 1 (to the right)
251	were correlated to more common gut taxa, including members of families Lachnospiraceae and
252	Rumminococceae. We defined the log2 fold ratio between the organisms separating PC 1 as a
253	tumor-survival index (Table S7, File S3). For every 2-fold increase in this index in tumor tissue,
254	the odds of survival increased by 20% (adjusted OR 0.80; 95% CI 0.67, 0.96). There were no
255	clear patterns in the taxa separating along PC 2, beyond the association between
256	Escherichia/Shigella and short-term survival (Table S8, File S3), although there was a significant
257	relationship between these selected taxa and survival (OR 0.64; 95% CI 0.41, 0.98 for every log2
258	increase).
259	
260	DISCUSSION
261	
262	Our regults show a clear and consistent difference between normal and tymer tissue once we had

Our results show a clear and consistent difference between normal and tumor tissue once we had 262 263 accounted for individual microbiome effects. Across all patients, tumors carried a higher 264 proportion of ASVs mapped to genus Fusobacterium, Gemella, Dialster and Campylobacter at 265 the expense of genera like *Blautia* and *Allistipes*. The tumor-associated features reflect 266 organisms found more commonly in CRC patients compared to healthy controls, whereas the 267 organisms associated with normal tissue belong to clades commonly associated with short chain 268 fatty acids and widely believed to be beneficial (5,6,49–51). Further, we are among the first to 269 show that the magnitude of the difference between the two tissue types can be associated with 270 prognosis. Our differential ranking analysis identified a set of 38 ASVs, which changed between

the tumor and normal tissue in short-term survivors, but not long-term survivors. This suggests
survival may be associated with localized changes in the microbiome.

273

274 We are among the first to report differences a different between tumor and normal tissue in 275 paired samples, let alone an association between the degree of dissimilarity and survival. Drewes 276 et al (12) demonstrated clear difference between paired tumor and normal tissue samples using 277 microscopy, although their 16S analysis did not explicitly test paired samples. These results 278 seemingly conflict with much of the existing literature (15-18,48). Several previous studies 279 reported no difference in the microbiome between the two tissue types, let alone an intra-280 individual difference associated with survival. Like the past studies, we observed and described a 281 strong intraindividual similarity. A personal microbial signature is a normal feature of the 282 microbiome seen in a variety of settings including population-based studies (10), dietary 283 interventions (52), and among CRC patients (15-18,48). However, unlike prior work, the 284 statistical models we selected accounted for this strong intra-individual similarity. Re-analysis of 285 prior publications using subject aware methods may identify the same patterns we found: strong 286 individual microbial signatures with a difference between the tissue types. Our results indicate 287 that the tumor-specific microenvironment, rather than the overall microbiome, is important for 288 understanding CRC pathology. At a minimum, future sequencing survey studies will need to 289 account for tissue-specific effects in their analysis, and studies treating tumor and non-tumor 290 biopsy samples as identical may need to check for biases.

291

Based on the difference in the microbiome between tissue types, we specifically focused on the relationship between the tumor microbiome and survival. Two previous studies have explored

294 the relationship between the tumor microbiome and survival using untargeted sequencing. In that 295 study of 67 Irish patients, Flemer and colleagues defined microbiome groups using a non-296 compositional abundance-based clustering approach (14). They found a higher relative 297 abundance of a cluster defined by members of genus Bacteriodetes, Blautia, Roseburia, 298 *Rumminococus*, and an unclassified member of family Lachnospiracae was associated with 299 shorter survival, while higher abundance of a cluster characterized by *Streptococcus*, 300 *Fusobacterium*, and unclassified family Enterobacteraceae was associated with longer survival. 301 These groupings are contradictory to the features associated with survival in our tumor tissue 302 results. In contrast, our tumor survival index, defined by an ALR of features along PC 1, showed 303 a decrease in the relative abundance in *Fusobacterium* among our long-term survivors, who were 304 characterized by a higher relative abundance of *Blautia*, *Roseburia*, among others. It is likely this 305 disagreement is due to differences in methods used for differential abundance (36,53). Our 306 results are more in line with results from a Chinese cohort (13). In that study, a higher 307 untransformed relative abundance of genus *Fusobacterium*, or higher relative abundance of reads 308 mapped to *Bacteriodetes fragilis* were associated with an increased hazard of death, while a 309 higher relative abundance of genus *Faecalibacterium* was protective. We find similar trends in 310 our tumor survival index, where short-term survival was associated with ASVs mapped to genus 311 Fusobacterium and a Bacteriodetes ASV, while longer survival was associated with 312 Faecalibacterium. Our results and those of the Chinese cohort suggest that a more normal (gut-313 like) microbiome is associated with long-term survival, while a more disrupted (oral) 314 microbiome led to a poor prognosis.

316 Our conclusions are supported by our nested case-control design, which helps establishing 317 temporality: changes in the local tumor microbiome at the time of surgery are associated with 318 future outcomes, increasing the probability that the observation is a real phenomenon, rather than 319 a change in the microbiome in response to disease state. Our analysis used statistically 320 appropriate methods, which accounted for analytical challenges in describing the microbiome, 321 decreasing the possibility of false positives, especially among the identified taxa (36,54). Our 322 analysis has also addressed confounders, which may affect the microbiome and survival, 323 including the strong individual microbiome signature. 324 325 However, our study has some limitations. First, our results focus on late-stage cancer patients in 326 northern Europe, and therefore may not be broadly generalizable. There are reports of 327 differences in the tumor microbiome between early and late stage CRC patients (55), and 328 differences in the healthy microbiome between countries (56). However, past work has suggested 329 that CRC is characterized by a set of organisms similar to the ones we identified, and our work 330 overlaps with the results of a Chinese cohort, despite methodological differences (5,6,13). 331 Additionally, we did not characterize our specific taxonomic profiles in a validation cohort, 332 meaning the taxa separating tissue types and the tumor survival index may be specific features of 333 our cohort, rather than able to predict survival in a broader population of late-stage CRC patients. 334 Finally, we profiled the microbiome using 16S rRNA sequencing, with all the assumptions, 335 benefits, and limitations of the technique. Our work is predicated on the assumption that 336 phylogenetic similarity correlates to genetic and niche similarity. Without robust functional 337 prediction and the ability to assemble genome units, we are limited in our mechanistic insight. 338 However, our 16S sequencing is, in many cases, able to capture species or sub-species level

resolution as the amplicon sequence variant ID, even if the name cannot be inferred accurately(57,58).

341

342 CONCLUSION

- 343 We performed a nested case-control of the role of the microbiome in relapse free survival
- following primary resection in late-stage CRC patients. We identified clear differences in the
- 345 microbiome between normal and tumor tissue and that a larger difference between tissue types
- 346 was associated with poor prognosis. We found the tumor microbiome was associated with
- 347 survival. This suggests a need to focus microbiome-based interventions at the tumor-specific
- 348 community, rather trying to modify prognosis by changing the gut microbiome overall.

349

350 DATA AVAILABILITY

351 Due to patient privacy concerns, sequences are available upon reasonable request. Patient data352 will not be released.

353

354 ACKNOWLEDGEMENTS

The authors wish to thank the Department of Surgery, County Hospital Ryhov, for the collection of tissue biopsies. Thanks to the lab core at Centre for Translational Microbiome Research for support in extracting, processing, and sequencing the samples. We are also grateful to Cameron Martino, Marcus Fedarko, and Kalen Cantrell for their rapid responses to bug reports and feature requests for the gemelli and empress qiime2 plugins.

360

362 FUNDING

- 363 This work was funded by Futurum-Academy for Healthcare, Region Jönköping County, Sweden
- 364 (grant FUTURUM-933436 and FUTURUM-809281), as well as centre grant from Ferring
- 365 Pharmaceuticals for the establishment of the Centre for Translational Microbiome Research.
- 366 JTM was funded by the intramural research program of the Eunice Kennedy Shriver National
- 367 Institute of Child Health and Human Development (NICHD).
- 368 The funders were not involved in the development, analysis, or interpretation of the study.

369

AUTHOR CONTRIBUTIONS

371 RSO, MS, LE, and AM designed the study. RSO collected the tissue samples and reviewed

372 medical records. JWD prepared the data. JWD performed the bioinformatic analysis; JWD and

373 NB analyzed the data with advice from JTM. JWD drafted the manuscript. All authors reviewed

and approved the final manuscript.

375

376 CONFLICTS OF INTEREST

377 The authors do not have any conflicts of interest.

379 **REFERENCES**

- Mattiuzzi C, Sanchis-Gomar F, Lippi G. Concise update on colorectal cancer epidemiology.
 Ann Transl Med [Internet]. 2019 Nov [cited 2021 May 7];7(21). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011596/
- Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality,
 survival, and risk factors. Prz Gastroenterol. 2019;14(2):89–103.
- Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science. 2001
 May 11;292(5519):1115–8.
- 4. Hooper LV, Midtvedt T, Gordon JI. How host-microbial interactions shape the nutrient
 environment of the mammalian intestine. Annu Rev Nutr. 2002;22:283–307.
- 5. Dai Z, Coker OO, Nakatsu G, Wu WKK, Zhao L, Chen Z, et al. Multi-cohort analysis of
 colorectal cancer metagenome identified altered bacteria across populations and universal
 bacterial markers. Microbiome. 2018 Apr 11;6(1):70.
- 392 6. Young C, Wood HM, Seshadri RA, Van Nang P, Vaccaro C, Melendez LC, et al. The
 393 colorectal cancer-associated faecal microbiome of developing countries resembles that of
 394 developed countries. Genome Medicine. 2021 Feb 16;13(1):27.
- Lauka L, Reitano E, Carra MC, Gaiani F, Gavriilidis P, Brunetti F, et al. Role of the
 intestinal microbiome in colorectal cancer surgery outcomes. World Journal of Surgical
 Oncology. 2019 Dec 2;17(1):204.
- Gethings-Behncke C, Coleman HG, Jordao HWT, Longley DB, Crawford N, Murray LJ, et al. Fusobacterium nucleatum in the Colorectum and Its Association with Cancer Risk and Survival: A Systematic Review and Meta-analysis. Cancer Epidemiol Biomarkers Prev.
 2020 Mar 1;29(3):539–48.
- 402 9. Byrd AL, Segre JA. Adapting Koch's postulates. Science. 2016 Jan 15;351(6270):224–6.
- 403 10. Chen L, Wang D, Garmaeva S, Vila AV, Gacesa R, Sinha T, et al. The long-term genetic
 404 stability and individual specificity of the human gut microbiome. Cell. 2021 Apr
 405 29;184(9):2302-2315.e12.
- 406 11. Gibson TE, Carey V, Bashan A, Hohmann EL, Weiss ST, Liu YY. On the Stability
 407 Landscape of the Human Gut Microbiome: Implications for Microbiome-based Therapies
 408 [Internet]. 2017 Aug [cited 2021 Nov 25] p. 176941. Available from:
 409 https://www.biorxiv.org/content/10.1101/176941v1
- 410
 12. Drewes JL, White JR, Dejea CM, Fathi P, Iyadorai T, Vadivelu J, et al. High-resolution
 411
 412
 412
 412
 413
 414
 414
 415
 415
 416
 416
 417
 417
 418
 418
 419
 419
 419
 410
 410
 410
 411
 411
 412
 412
 412
 412
 412
 414
 415
 415
 416
 417
 417
 418
 418
 418
 419
 419
 419
 410
 410
 410
 411
 411
 412
 412
 412
 412
 412
 412
 413
 414
 414
 414
 415
 415
 416
 417
 417
 418
 418
 418
 419
 419
 410
 410
 410
 411
 411
 412
 412
 412
 412
 412
 412
 414
 414
 415
 415
 416
 417
 418
 418
 418
 419
 419
 419
 410
 410
 411
 411
 412
 412
 412
 412
 412
 412
 412
 412
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414

413 13. Wei Z, Cao S, Liu S, Yao Z, Sun T, Li Y, et al. Could gut microbiota serve as prognostic 414 biomarker associated with colorectal cancer patients' survival? A pilot study on relevant 415 mechanism. Oncotarget. 2016 Jun 15;7(29):46158-72. 416 14. Flemer B, Herlihy M, O'Riordain M, Shanahan F, O'Toole PW. Tumour-associated and 417 non-tumour-associated microbiota: Addendum. Gut Microbes. 2018 Jul 4;9(4):369-73. 418 15. Chen W, Liu F, Ling Z, Tong X, Xiang C. Human Intestinal Lumen and Mucosa-419 Associated Microbiota in Patients with Colorectal Cancer. PLOS ONE. 2012 Jun 420 28;7(6):e39743. 421 16. Wirth U, Garzetti D, Jochum LM, Spriewald S, Kühn F, Ilmer M, et al. Microbiome 422 Analysis from Paired Mucosal and Fecal Samples of a Colorectal Cancer Biobank. Cancers. 2020 Dec;12(12):3702. 423 424 17. Leung PHM, Subramanya R, Mou Q, Lee KT wei, Islam F, Gopalan V, et al. 425 Characterization of Mucosa-Associated Microbiota in Matched Cancer and Non-neoplastic 426 Mucosa From Patients With Colorectal Cancer. Frontiers in Microbiology [Internet]. 2019 427 [cited 2021 Oct 12];10. Available from: 428 https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC6581718/ 429 18. Sheng QS, He KX, Li JJ, Zhong ZF, Wang FX, Pan LL, et al. Comparison of Gut 430 Microbiome in Human Colorectal Cancer in Paired Tumor and Adjacent Normal Tissues. 431 Onco Targets Ther. 2020 Jan 21;13:635–46. 432 19. Debesa-Tur G, Pérez-Brocal V, Ruiz-Ruiz S, Castillejo A, Latorre A, Soto JL, et al. 433 Metagenomic analysis of formalin-fixed paraffin-embedded tumor and normal mucosa 434 reveals differences in the microbiome of colorectal cancer patients. Scientific Reports. 2021 435 Jan 11;11(1):391. 20. Hugerth LW, Seifert M, Pennhag A a. L, Du J, Hamsten MC, Schuppe-Koistinen I, et al. A 436 437 comprehensive automated pipeline for human microbiome sampling, 16S rRNA gene 438 sequencing and bioinformatics processing. bioRxiv. 2018 Mar 21;286526. 439 21. Hugerth LW, Wefer HA, Lundin S, Jakobsson HE, Lindberg M, Rodin S, et al. DegePrime, 440 a Program for Degenerate Primer Design for Broad-Taxonomic-Range PCR in Microbial 441 Ecology Studies. Appl Environ Microbiol. 2014 Aug 15;80(16):5116-23. 22. 442 Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. DADA2: 443 High-resolution sample inference from Illumina amplicon data. Nature Methods. 2016 444 Jul;13(7):581–3. 445 23. Wang Q, Garrity GM, Tiedje JM, Cole JR. Naïve Bayesian Classifier for Rapid Assignment 446 of rRNA Sequences into the New Bacterial Taxonomy. Appl Environ Microbiol. 2007 Aug 447 15;73(16):5261-7.

448 24. Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, et al. The SILVA ribosomal 449 RNA gene database project: improved data processing and web-based tools. Nucleic Acids 450 Res. 2013 Jan;41(Database issue):D590-596. 451 25. Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, et al. 452 Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. 453 Nature Biotechnology. 2019 Aug;37(8):852-7. 454 26. Janssen S, McDonald D, Gonzalez A, Navas-Molina JA, Jiang L, Xu ZZ, et al. 455 Phylogenetic Placement of Exact Amplicon Sequences Improves Associations with Clinical 456 Information. mSystems [Internet]. 2018 Jun 26 [cited 2021 Feb 8];3(3). Available from: 457 https://msystems.asm.org/content/3/3/e00021-18

458 27. Lozupone C, Knight R. UniFrac: a new phylogenetic method for comparing microbial
459 communities. Appl Environ Microbiol. 2005 Dec;71(12):8228–35.

460 28. Lozupone CA, Hamady M, Kelley ST, Knight R. Quantitative and qualitative beta diversity
461 measures lead to different insights into factors that structure microbial communities. Appl
462 Environ Microbiol. 2007 Mar;73(5):1576–85.

- 463 29. Jaccard P. The Distribution of the Flora in the Alpine Zone.1. New Phytologist.
 464 1912;11(2):37–50.
- 30. Sørensen TJ. A method of establishing groups of equal amplitude in plant sociology based
 on similarity of species content and its application to analyses of the vegetation on Danish
 commons. København: I kommission hos E. Munksgaard; 1948.
- 468 31. Weiss S, Xu ZZ, Peddada S, Amir A, Bittinger K, Gonzalez A, et al. Normalization and
 469 microbial differential abundance strategies depend upon data characteristics. Microbiome.
 470 2017 Mar 3;5(1):27.
- 471 32. Gloor GB, Macklaim JM, Pawlowsky-Glahn V, Egozcue JJ. Microbiome Datasets Are
 472 Compositional: And This Is Not Optional. Front Microbiol. 2017;8:2224.
- 473 33. Aitchison J, Barceló-Vidal C, Martín-Fernández JA, Pawlowsky-Glahn V. Logratio
 474 Analysis and Compositional Distance. Mathematical Geology. 2000 Apr 1;32(3):271–5.
- 475 34. Martino C, Shenhav L, Marotz CA, Armstrong G, McDonald D, Vázquez-Baeza Y, et al.
 476 Context-aware dimensionality reduction deconvolutes gut microbial community dynamics.
 477 Nature Biotechnology. 2021 Feb;39(2):165–8.
- 478 35. Martino C, Morton JT, Marotz CA, Thompson LR, Tripathi A, Knight R, et al. A Novel
 479 Sparse Compositional Technique Reveals Microbial Perturbations. mSystems [Internet].
- 480 2019 Feb 26 [cited 2020 May 4];4(1). Available from:
- 481 https://msystems.asm.org/content/4/1/e00016-19

36. Morton JT, Marotz C, Washburne A, Silverman J, Zaramela LS, Edlund A, et al.

482

483 Establishing microbial composition measurement standards with reference frames. Nat 484 Commun. 2019 20;10(1):2719. 485 37. Morton JT, Jin DM, Mills RH, Shao Y, Rahman G, Berding K, et al. Multi-omic analysis 486 along the gut-brain axis points to a functional architecture of autism [Internet]. bioRxiv; 487 2022 [cited 2022 Mar 2]. p. 2022.02.25.482050. Available from: 488 https://www.biorxiv.org/content/10.1101/2022.02.25.482050v1 489 38. Carpenter B, Gelman A, Hoffman MD, Lee D, Goodrich B, Betancourt M, et al. Stan: A 490 Probabilistic Programming Language. Journal of Statistical Software. 2017 Jan 11;76:1–32. 491 39. Sorensen T, Hohenstein S, Vasishth S. Bayesian linear mixed models using Stan: A tutorial 492 for psychologists, linguists, and cognitive scientists. The Quantitative Methods for 493 Psychology. 2016;12(3):175–200. 494 40. Anderson MJ. A new method for non-parametric multivariate analysis of variance. Austral 495 Ecology. 2001;26(1):32-46. 496 41. Seabold S, Perktold J. Statsmodels: Econometric and Statistical Modeling with Python. 497 Proceedings of the 9th Python in Science Conference. 2010 Jan 1;2010. 498 42. Virtanen P, Gommers R, Oliphant TE, Haberland M, Reddy T, Cournapeau D, et al. SciPy 499 1.0: fundamental algorithms for scientific computing in Python. Nature Methods. 2020 500 Mar;17(3):261–72. 501 43. Harris CR, Millman KJ, van der Walt SJ, Gommers R, Virtanen P, Cournapeau D, et al. 502 Array programming with NumPy. Nature. 2020 Sep;585(7825):357–62. 503 44. Cantrell K, Fedarko MW, Rahman G, McDonald D, Yang Y, Zaw T, et al. EMPress 504 Enables Tree-Guided, Interactive, and Exploratory Analyses of Multi-omic Data Sets. 505 mSystems. 6(2):e01216-20. 506 45. Vázquez-Baeza Y, Pirrung M, Gonzalez A, Knight R. EMPeror: a tool for visualizing high-507 throughput microbial community data. GigaScience [Internet]. 2013 Dec 1 [cited 2021 Feb 508 8];2(2047-217X-2-16). Available from: https://doi.org/10.1186/2047-217X-2-16 509 46. Dahl E, Neer E, Karstens L. A custom color palette for improving data visualization 510 [Internet]. [cited 2022 Jan 12]. Available from: https://karstenslab.github.io/microshades/ 511 47. Hugerth LW, Andreasson A, Talley NJ, Forsberg AM, Kjellström L, Schmidt PT, et al. No 512 distinct microbiome signature of irritable bowel syndrome found in a Swedish random 513 population. Gut. 2020 Jun;69(6):1076-84. 514 48. Flemer B, Lynch DB, Brown JMR, Jeffery IB, Ryan FJ, Claesson MJ, et al. Tumour-515 associated and non-tumour-associated microbiota in colorectal cancer. Gut. 2017 516 Apr;66(4):633–43.

517	49.	Vacca M, Celano G, Calabrese FM, Portincasa P, Gobbetti M, De Angelis M. The
518		Controversial Role of Human Gut Lachnospiraceae. Microorganisms. 2020 Apr;8(4):573.
519 520 521	50.	Barcenilla A, Pryde SE, Martin JC, Duncan SH, Stewart CS, Henderson C, et al. Phylogenetic Relationships of Butyrate-Producing Bacteria from the Human Gut. Applied and Environmental Microbiology. 2000 Apr;66(4):1654–61.
522 523 524	51.	Hajjar R, Richard CS, Santos MM. The role of butyrate in surgical and oncological outcomes in colorectal cancer. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2021 Apr;320(4):G601–8.
525 526	52.	Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011 Oct 7;334(6052):105–8.
527 528 529	53.	Nearing JT, Douglas GM, Hayes M, MacDonald J, Desai D, Allward N, et al. Microbiome differential abundance methods produce disturbingly different results across 38 datasets. 2021 May 10;2021.05.10.443486.
530 531	54.	Gloor GB, Macklaim JM, Pawlowsky-Glahn V, Egozcue JJ. Microbiome Datasets Are Compositional: And This Is Not Optional. Frontiers in Microbiology. 2017;8:2224.
532 533 534	55.	Yachida S, Mizutani S, Shiroma H, Shiba S, Nakajima T, Sakamoto T, et al. Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. Nat Med. 2019 Jun;25(6):968–76.
535 536 537	56.	McDonald D, Hyde E, Debelius JW, Morton JT, Gonzalez A, Ackermann G, et al. American Gut: an Open Platform for Citizen Science Microbiome Research. mSystems. 2018 Jun;3(3).
538 539	57.	Callahan BJ, McMurdie PJ, Holmes SP. Exact sequence variants should replace operational taxonomic units in marker-gene data analysis. ISME J. 2017 Dec;11(12):2639–43.
540 541 542	58.	Eren AM, Borisy GG, Huse SM, Mark Welch JL. Oligotyping analysis of the human oral microbiome. Proceedings of the National Academy of Sciences. 2014 Jul 15;111(28):E2875–84.

Supplemental tables

Table S1. Patient characteristics in the cohort

Table S2. Per-subject predictors of the microbiome in CTF ordination space

Table S3. ASVs separating normal and tumor tissue based on differential ranking

Table S4. ASVs associated with the survival term in the interaction differential ranking model

Table S5. ASVs associated with the tissue term in the interaction differential ranking model

Table S6. ASVs associated with the interaction term in the interaction differential ranking model

Table S7. ASVs used for the tumor rPCA ALR calculation

Supplemental Figures

Figure S1. A family level view of the microbiome

Figure S2. There is a strong individual effect on the microbiome

Figure S3. Metadata predictors of the microbiome in Compositional Tensor Factorization (CTF) space

Figure S4. Survival separates individuals by tumor-associated PCA quadrant

Supplemental Files

File S1. Representative sequences separating tumor tissue

File S2. Representative sequences identified in the interaction model

File S3. Representative sequences for ASVs associated with PC1 in rPCA space

File S4. STORMS checklist





